#10

SEQUENCE LISTING

<110> SMYTHE, MARK LESLIE
MEUTERMANS, WIM DENIS FRANS
BOURNE, GREGORY THOMAS
MCGEARY, ROSS PETER

<120> SYNTHESIS OF CYCLIC PEPTIDES

<130> 4050.001200

<140> 09/806,036
<141> 2001-07-05

<150> PCT/AU99/00813
<151> 1999-09-24

<150> AU PP 6164
<151> 1998-09-25

<160> 76

<170> PatentIn version 3.2

<210> 1
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = CAT-Arg

<400> 1

Asp Gly Xaa Gly
1

<210> 2
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 2

Xaa Xaa Arg Phe
1

<210> 3
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 3

Tyr Arg Phe Gly
1

<210> 4
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 4

Xaa Arg Phe Gly
1

<210> 5
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 5

Xaa Arg Phe Gly
1

<210> 6
<211> 4
<212> PRT

<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 6

Gly Gly Gly Gly
1

<210> 7
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Sarcosine

<400> 7

Gly Gly Gly Xaa
1

<210> 8
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = Sarcosine

<400> 8

Gly Gly Xaa Gly
1

<210> 9
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)

<223> Xaa = Sarcosine

<400> 9

Gly Xaa Gly Gly
1

<210> 10
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(4)
<223> Xaa = Sarcosine

<400> 10

Gly Gly Xaa Xaa
1

<210> 11
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Sarcosine

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Sarcosine

<400> 11

Gly Xaa Gly Xaa
1

<210> 12
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC_FEATURE
<222> (2)..(3)
<223> Xaa = Sarcosine

<400> 12

Gly Xaa Xaa Gly
1

<210> 13
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(4)
<223> Xaa = Sarcosine

<400> 13

Gly Xaa Xaa Xaa
1

<210> 14
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Asp substituted with OBu

<400> 14

Xaa Val Gly Leu
1

<210> 15
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Asp substituted with OBu

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = 2-hydroxy-4-methoxybenzyl-Val

<400> 15

Xaa Xaa Gly Leu
1

<210> 16
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Asp substituted with OBu

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = 2-hydroxy-4-methoxybenzyl-Gly

<400> 16

Xaa Val Xaa Leu
1

<210> 17
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 17

Ala Phe Leu Pro Ala
1 5

<210> 18
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 18

Ala Phe Leu Pro Ala
1 5

<210> 19
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 19

Xaa Leu Pro Ala Ala
1 5

<210> 20
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 20

Phe Leu Pro Ala Ala
1 5

<210> 21
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = NH2CH2CH2SSCH2CH2-Gly

<400> 21

Xaa Arg Pro Phe Gly
1 5

<210> 22
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = HSCH2CH2-Gly

<400> 22

Xaa Arg Phe Gly
1

<210> 23
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = SCH2CH2-Gly

<400> 23

Xaa Arg Pro Phe Gly
1 5

<210> 24
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = HSCH2CH2-Gly

<400> 24

Xaa Arg Pro Phe Gly
1 5

<210> 25
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Gly substituted with CH2CH2SH

<400> 25

Xaa Arg Pro Phe Gly
1 5

<210> 26
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(5-nitro-2-hydroxybenzyl)-Ala

<400> 26

Xaa Phe Leu Pro Ala
1 5

<210> 27
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Ala

<400> 27

Xaa Phe Leu Pro Ala
1 5

<210> 28
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 28

Xaa Leu Pro Ala Ala
1 5

<210> 29
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 29

Tyr Ala Phe Gly
1

<210> 30
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 30

Phe Leu Pro Ala Ala
1 5

<210> 31
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 31

Xaa Arg Phe Gly
1

<210> 32
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 32

Tyr Xaa Phe Gly
1

<210> 33
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 33

Tyr Arg Xaa Gly
1

<210> 34
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 34

Xaa Xaa Phe Gly
1

<210> 35
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 35

Xaa Arg Xaa Gly
1

<210> 36
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 36

Xaa Xaa Phe Gly
1

<210> 37
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 37

Xaa Arg Xaa Gly
1

<210> 38
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 38

Xaa Xaa Arg Phe
1

<210> 39
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTEHTIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 39

Xaa Tyr Xaa Phe
1

<210> 40
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTEHTIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 40

Xaa Tyr Arg Xaa
1

<210> 41
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 41

Gly Tyr Arg Phe
1

<210> 42
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 42

Tyr Arg Phe Ala
1

<210> 43
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (3)..(3)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 43

Xaa Arg Xaa Ala
1

<210> 44
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 44

Xaa Arg Xaa Ala
1

<210> 45
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Ala

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 45

Xaa Tyr Xaa Phe
1

<210> 46
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 46

Xaa Xaa Phe Gly
1

<210> 47
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 47

Tyr Arg Phe Gly
1

<210> 48
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 48

Gly Tyr Arg Phe
1

<210> 49
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = CAT-Arg

<400> 49

Asp Gly Xaa Gly
1

<210> 50
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = Amb-Arg

<400> 50

Asp Gly Xaa Gly
1

<210> 51
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Amb-Gly

<400> 51

Asp Xaa Arg Gly
1

<210> 52
<211> 8
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = Amb-Arg

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = Amb-Arg

<400> 52

Asp Gly Xaa Gly Asp Gly Xaa Gly
1 5

<210> 53
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Me-Phe

<400> 53

Ala Xaa Leu Pro Ala
1 5

<210> 54
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Phe substituted with Me

<400> 54

Ala Xaa Leu Pro Ala
1 5

<210> 55
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = a ring contraction auxiliary comprising O or S linked to Tyr

<220>

<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Gly linked to an activated or safety catch linker linked to resin

<400> 55

Xaa Arg Phe Xaa
1

<210> 56
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = a ring contraction auxiliary comprising O or S linked to Arg

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Tyr linked to an activated or safety catch linker linked to resin

<400> 56

Xaa Phe Gly Xaa
1

<210> 57
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = a ring contraction auxiliary comprising O or S linked to Phe

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Arg linked to an activated or safety catch linker linked to resin

<400> 57

Xaa Gly Tyr Xaa
1

<210> 58
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = a ring contraction auxiliary comprising O or S linked to Gly

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Phe linked to an activated or safety catch linker linked to resin

<400> 58

Xaa Tyr Arg Xaa
1

<210> 59
<211> 7
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 59

Pro Phe Asn Ser Leu Ala Ile
1 5

<210> 60
<211> 7
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 60

Asn Ser Leu Ala Ile Pro Phe
1 5

<210> 61
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<400> 61

Phe Phe Phe Phe
1

<210> 62
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Beta-Ala

<400> 62

Phe Trp Lys Gly Xaa
1 5

<210> 63
<211> 7
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 63

Pro Phe Asn Ser Leu Ala Ile
1 5

<210> 64
<211> 14
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 64

Asn Ser Leu Ala Ile Pro Phe Asn Ser Leu Ala Ile Pro Phe
1 5 10

<210> 65
<211> 21
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 65

Asn Ser Leu Ala Ile Pro Phe Asn Ser Leu Ala Ile Pro Phe Asn Ser
1 5 10 15

Leu Ala Ile Pro Phe
20

<210> 66
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Beta-Ala

<400> 66

Leu Asp Val Gly Xaa
1 5

<210> 67
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Beta-Ala

<400> 67

Arg Gly Asp Gly Xaa
1 5

<210> 68
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)

<223> Xaa = Beta-Ala

<400> 68

Phe Lys Trp Gly Xaa
1 5

<210> 69
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = substituted Pro

<400> 69

Ala Phe Leu Xaa
1

<210> 70
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 70

Tyr Arg Phe Gly
1

<210> 71
<211> 7
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 71

Tyr Ala Phe Gly Tyr Pro Ser
1 5

<210> 72
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 72

Ala Pro Leu Phe Ala
1 5

<210> 73
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Pro-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Alanine allyl ester appended to resin

<400> 73

Ala Phe Leu Xaa
1

<210> 74
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-4-nitrobenzyl)-Ala

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Pro-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Alanine allyl ester linked to resin

<400> 74

Xaa Phe Leu Xaa
1

<210> 75
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-4-nitrobenzyl)-Ala

<400> 75

Xaa Phe Leu Pro Ala
1 5

<210> 76
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = a ring contraction auxiliary containing O or S linked to Ala

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Pro-Backbone linker and resin

<400> 76

Xaa Xaa Leu Xaa Ala
1 5